Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.41−0.07 (-14.34%)
Close on Nov 18, 2026Market cap $63.33MP/E –Yield –
Coherus Oncology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Coherus Oncology's operating income for the twelve months ending Jun 30, 2026 was -$158.70M. For fiscal 2025 it was -$181.13M. The highest annual figure on record is $156.32M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$181.13M | – |
| FY2024 | Dec 31, 2024 | -$199.65M | – |
| FY2023 | Dec 31, 2023 | -$203.20M | – |
| FY2022 | Dec 31, 2022 | -$256.88M | – |
| FY2021 | Dec 31, 2021 | -$263.86M | -268.8% |
| FY2020 | Dec 31, 2020 | $156.32M | +45.1% |
| FY2019 | Dec 31, 2019 | $107.77M | – |
| FY2018 | Dec 31, 2018 | -$204.42M | – |
| FY2017 | Dec 31, 2017 | -$232.14M | – |
| FY2016 | Dec 31, 2016 | -$115.93M | – |
| FY2015 | Dec 31, 2015 | -$219.07M | – |
| FY2014 | Dec 31, 2014 | -$64.68M | – |
| FY2013 | Dec 31, 2013 | -$35.99M | – |
| FY2012 | Dec 31, 2012 | -$38.52M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$32.33M | – |
| Q1 FY2026 | Mar 31, 2026 | -$36.15M | – |
| Q4 FY2025 | Dec 31, 2025 | -$45.88M | – |
| Q3 FY2025 | Sep 30, 2025 | -$44.33M | – |
| Q2 FY2025 | Jun 30, 2025 | -$45.49M | – |
| Q1 FY2025 | Mar 31, 2025 | -$45.44M | – |
| Q4 FY2024 | Dec 31, 2024 | -$45.38M | – |
| Q3 FY2024 | Sep 30, 2024 | -$46.86M | – |
| Q2 FY2024 | Jun 30, 2024 | -$39.63M | – |
| Q1 FY2024 | Mar 31, 2024 | -$67.79M | – |
| Q4 FY2023 | Dec 31, 2023 | -$68.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -$32.01M | – |
| Q2 FY2023 | Jun 30, 2023 | -$34.54M | – |
| Q1 FY2023 | Mar 31, 2023 | -$67.75M | – |
| Q4 FY2022 | Dec 31, 2022 | -$51.49M | – |
| Q3 FY2022 | Sep 30, 2022 | -$80.45M | – |
| Q2 FY2022 | Jun 30, 2022 | -$44.01M | – |
| Q1 FY2022 | Mar 31, 2022 | -$80.93M | – |
| Q4 FY2021 | Dec 31, 2021 | -$39.55M | -340.8% |
| Q3 FY2021 | Sep 30, 2021 | -$32.79M | -197.2% |
| Q2 FY2021 | Jun 30, 2021 | -$24.16M | -137.0% |
| Q1 FY2021 | Mar 31, 2021 | -$167.36M | -509.5% |
| Q4 FY2020 | Dec 31, 2020 | $16.43M | -63.5% |
| Q3 FY2020 | Sep 30, 2020 | $33.72M | -35.0% |
| Q2 FY2020 | Jun 30, 2020 | $65.31M | +137.6% |
| Q1 FY2020 | Mar 31, 2020 | $40.87M | – |
| Q4 FY2019 | Dec 31, 2019 | $45.03M | – |
| Q3 FY2019 | Sep 30, 2019 | $51.84M | – |
| Q2 FY2019 | Jun 30, 2019 | $27.49M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.60M | – |
| Q4 FY2018 | Dec 31, 2018 | -$60.50M | – |
| Q3 FY2018 | Sep 30, 2018 | -$56.97M | – |
| Q2 FY2018 | Jun 30, 2018 | -$44.91M | – |
| Q1 FY2018 | Mar 31, 2018 | -$42.03M | – |
| Q4 FY2017 | Dec 31, 2017 | -$46.47M | – |
| Q3 FY2017 | Sep 30, 2017 | -$56.62M | -166.9% |
| Q2 FY2017 | Jun 30, 2017 | -$56.64M | – |
| Q1 FY2017 | Mar 31, 2017 | -$72.42M | – |
| Q4 FY2016 | Dec 31, 2016 | -$73.46M | – |
| Q3 FY2016 | Sep 30, 2016 | $84.62M | – |
See a number that looks wrong?